<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085549</url>
  </required_header>
  <id_info>
    <org_study_id>BOAE</org_study_id>
    <nct_id>NCT04085549</nct_id>
  </id_info>
  <brief_title>Effects of a Berry Oil Cream on Atopic Eczema and Skin</brief_title>
  <official_title>Effects of a Berry Oil Cream on Atopic Eczema and Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Petra Larmo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cliniscan Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aromtech Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic eczema is a chronic inflammatory skin disease associated with itch and inflammatory
      lesions in typical skin areas. The objective of this study is to investigate the effects of a
      cream containing berry and plant oils and humectants on atopic eczema and dry skin.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study was suspended due to Covid-19 situation.
  </why_stopped>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study has two parts. In part 1 the participants, care provider and outcome assessor know which treatment is given to each skin area. In part 2 participant, care provider, investigator and outcome assessor do not know which treatment is given to each skin area. Masking is done by identical cream tubes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in severity of atopic eczema</measure>
    <time_frame>Part 1: Baseline, 2 weeks. Part 2: Baseline, 5 weeks</time_frame>
    <description>Objective local Scoring Atopic Dermatitis (SCORAD) index. Scale range for objective local scorad in study part 1 (chosen eczema lesion) 0-63, in study part 2 (body half) 0-73. Decrease indicates better outcome/ milder symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in severity of symptoms</measure>
    <time_frame>Part 1: Baseline, 2 weeks. Part 2: Baseline, 2 weeks, 5 weeks</time_frame>
    <description>Modified Patient Oriented Eczema Measure (POEM) questionnaire. Scale range: 0-24. Decrease indicates better outcome/ milder symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sensation of itch</measure>
    <time_frame>Part 1: Baseline, 2 weeks. Part 2: Baseline, 2 weeks, 5 weeks</time_frame>
    <description>Visual Analog Scale (VAS) evaluation. Scale range 0-10. Decrease indicates better outcome/ milder symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in transepidermal water loss (TEWL)</measure>
    <time_frame>Part 1: Baseline, 2 weeks. Part 2: Baseline, 2 weeks, 5 weeks</time_frame>
    <description>Measurement of TEWL (g/m2h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin hydration</measure>
    <time_frame>Part 1: Baseline, 2 weeks. Part 2: Baseline, 2 weeks, 5 weeks</time_frame>
    <description>Measurement of moisture (capacitance, proportional to water content of skin)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin pH</measure>
    <time_frame>Part 1: Baseline, 2 weeks. Part 2: Baseline, 2 weeks, 5 weeks</time_frame>
    <description>Measurement of skin pH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms of itching, dryness, flaking of skin</measure>
    <time_frame>Part 1: Baseline, 2 weeks. Part 2: Baseline, 2 weeks, 5 weeks</time_frame>
    <description>Symptom logbooks: daily scoring from 0 (no symptoms) to 3 (severe symptoms)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Atopic Dermatitis Eczema</condition>
  <arm_group>
    <arm_group_label>Berry Oil Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study part 1: Administered to a chosen eczema lesion on randomized body half 1-2 times/d or more frequently (use reported to study logbook) for two weeks. Also administered to forearm (randomized body half) twice/d for two weeks. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Study part 1: A chosen eczema lesion on randomized body half is an untreated control for two weeks. Also one forearm (on randomized body half) is a control with no treatment for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A commercial reference cream, not containing berry and plant oils. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Berry Oil Cream</intervention_name>
    <description>Cream containing berry and plant oils and humectants; a medical device product in development</description>
    <arm_group_label>Berry Oil Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reference Cream</intervention_name>
    <description>Commercial refence cream not containing berry and plant oils.</description>
    <arm_group_label>Reference cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atopic Eczema (mild or medium severity)

        Exclusion Criteria:

          -  Other serious skin conditions (for example psoriasis)

          -  Known hypersensitivity to ingredients of the study creams

          -  Medication seriously affecting immune function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Risto Oksman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniscan Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mehil√§inen (Private Clinic)</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aromtech Ltd.</investigator_affiliation>
    <investigator_full_name>Petra Larmo</investigator_full_name>
    <investigator_title>Ph.D., R&amp;D Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

